Bispecific Antibodies for Blood Cancers — how they work, and what India can actually get

A bispecific antibody is a laboratory-made antibody with two different arms instead of one. One arm grips a marker on the blood-cancer cell. The other grips a T cell. Holding both at once pulls the two together, so your own T cell is switched on right beside the cancer cell. It arrives ready-made, in a vial.

Most families meet the term in the same conversation as CAR-T, and leave that conversation unsure whether they have been offered one thing or two. They are two different things. Both put T cells to work against a blood cancer. Only one of them takes cells out of your body first.

This page names classes and targets, not products. The individual medicines built this way are prescription-only, and whether any of them fits a particular person is a prescribing decision made by a treating team with the full case in front of it. No brand is named here, and no medicine is compared against another.

It also helps to place the class. This is immunotherapy in the strict sense — the drug does not attack the cancer cell itself, it recruits your immune system to do it. That is a different mechanism from chemotherapy, and a different mechanism again from the older immunotherapies, interferon and interleukin, which flooded the whole body with immune signals rather than aiming one cell at another.

1. 1

   One arm grips a marker on the blood-cancer cell

   Blood-cancer cells carry proteins on their surface that are far more common on the cancer than on healthy tissue, which makes them usable as a handle. CD19 and CD20 are the handles used on many B-cell leukaemias and lymphomas. BCMA is one of the handles used on myeloma cells.

2. 2

   The other arm grips CD3 on any passing T cell

   CD3 is part of the switch every T cell uses to decide whether to act. The second arm holds that switch. It does not care which T cell it catches, which is why this class does not depend on your T cells having recognised the cancer beforehand.

3. 3

   Holding both forces the two cells into contact

   The antibody works as a physical bridge. The T cell and the cancer cell are pulled close enough to form the tight junction a T cell needs before it will fire. Distance is normally what protects a cancer cell from a T cell. The bridge removes it.

4. 4

   Your own T cell does the work

   Nothing exotic follows. The T cell releases the same proteins it uses against a virus-infected cell. The medicine makes the introduction; the immune system does the rest. That is also why the reaction can come on suddenly, and why the dosing schedule is built the way it is.

Mechanism framing here follows NCCN, ASCO and ESMO patient-education and toxicity-management material, current as of August 2026. CD3, CD19, CD20 and BCMA are biological targets on cells, not the names of medicines.

Settings above reflect NCCN and ESMO guidance current as of August 2026 and describe disease groups, not products. Approval somewhere in the world is not the same as availability in India — that is a separate question, taken up further down this page.

One practical point families ask about early: the first doses of this class are not given like the rest, and many protocols need a hospital bed for them. Step-up dosing and hospital admission for bispecific therapy sets out what those first two weeks actually involve.

This table compares two classes of treatment, not two products, and says nothing about which produces a better result for any individual. That is a decision for a haemato-oncology team looking at your disease, your previous lines of treatment and your fitness.

Families who have already been through a transplant sometimes meet a third option that also uses donor immune cells directly — donor lymphocyte infusion after transplant explains where that one fits.

Partly, and medicine by medicine rather than class by class. Every individual product needs its own CDSCO approval and a supply route before an Indian patient can receive it. Some are approved and marketed here. Some reach patients only through named-patient import. Some are not available at all.

What is genuinely available changes. A page cannot be the source of truth on this, and neither can a forum post or a news article from another country. Ask the treating haemato-oncologist what can actually be obtained for your diagnosis, in what timeframe, and at what cost — and ask it again if months have passed, because approvals and supply both move.

Access is also concentrated. The first doses in this class need monitoring capacity, which means a small number of centres are in a position to start one. That is a practical constraint on top of the regulatory one, and it is worth asking about early rather than after a decision has been made.

What CION does and does not do. Immunotherapy is administered as day care at CION centres, on prescription and after assessment. Response-assessment PET-CT is coordinated at partner imaging centres, not owned by CION. CION does not provide CAR-T or any cell therapy — for those, our role is orientation and referral only. Nothing on this page is a statement that CION supplies any particular medicine in this class.

If you are still working out which of the many things called immunotherapy applies to your case, the immunotherapy at CION Cancer Clinics hub lays the classes out side by side.

1. 1

   Confirm the handle is actually on your cancer

   An antibody aimed at CD19, CD20 or BCMA is pointless if your cancer does not carry it. That is checked on the marrow or biopsy sample, usually by flow cytometry or immunophenotyping, alongside baseline blood counts and infection screening.

2. 2

   Expect step-up dosing in the first cycle

   A small first dose, a larger second, then the full amount. Engaging many T cells at once is what causes the early reaction, so the schedule eases into it. Steroid, antihistamine and paracetamol premedication is standard before those doses.

3. 3

   Plan for monitoring, and treat fever as an emergency

   Many protocols require admission or extended observation for the step-up doses. A caregiver should stay with you, and you should remain within reach of the treating hospital for several days after each early dose. Fever after a dose means go in now — do not manage it at home.

4. 4

   Later doses settle into a routine

   Once the ramp-up is complete and tolerated, most regimens move to a repeating outpatient schedule. At CION centres immunotherapy is administered as day care: you are observed during and after the dose and go home the same day.

If a fever, breathlessness, confusion or a drop in blood pressure appears after a dose, contact the treating team or go to the nearest emergency department immediately. CION patients can also call 1800 202 8726 at any hour.

• Step-up dosing and hospital admission for bispecific therapy — what the first two weeks look like, why a bed is often needed, and what is being watched for.
• Donor lymphocyte infusion after transplant — the other way donor immune cells are used directly against a blood cancer, and where it sits in the sequence.
• Interferon and interleukin: the older immunotherapies — the generation before this one, and why the mechanism changed.
• Immunotherapy at CION Cancer Clinics — the hub, with every class of immunotherapy set out side by side.

One conversation before you commit to anything

Blood-cancer decisions are made quickly and under pressure. A second opinion costs you nothing and takes 45 unhurried minutes with a specialist who will explain the options, including the option of waiting.